PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer

被引：0
|
作者：
Metzger-Filho, Otto
Mandrekar, Sumithra
Loibl, Sibylle
Ciruelos, Eva
Gianni, Luca
Lim, Elgene
Miller, Kathy
Huang, Cynthia
Koehler, Maria
Francis, Prue
Valagussa, Pinuccia
Goel, Shom
Prat, Aleix
Goetz, Matthew
Loi, Sherene
Krop, Ian
Carey, Lisa
Lanzillotti, Jane
Winer, Eric
Tripathy, Debu
DeMichele, Angela
机构：
[1] Alliance Fdn Trials, Boston, MA USA
[2] German Breast Grp, Neu Isenburg, Germany
[3] Australia & New Zealand Breast Canc Trials Grp, Newcastle, NSW, Australia
[4] Fdn Michelangelo, Milan, Italy
[5] Pfizer, New York, NY USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-05-07
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer
    Metzger, O.
    Mandrekar, S.
    Ciruelos, E.
    Loibl, S.
    Valagussa, P.
    Demichele, A. M.
    Lim, E.
    Tripathy, D.
    Winer, E.
    Huang, C.
    Khoeler, M.
    Carey, L.
    Francis, P.
    Miller, K.
    Goel, S.
    Goetz, M. P.
    Prat, A.
    Loi, S.
    Krop, I.
    Gianni, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2+therapy plus endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR1)/HER2-positive metastatic breast cancer (MBC)
    Loibl, S.
    Metzger, O.
    Mandrekar, S. J.
    Mundhenke, C.
    Seiler, S.
    Valagussa, P.
    DeMichele, A.
    Lim, E.
    Tripathy, D.
    Winer, E. P.
    Huang, C.
    Carey, L.
    Francis, P.
    Miller, K. D.
    Goetz, M. P.
    Prat, A.
    Loi, S.
    Krop, I.
    Gianni, L.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2018, 29 : 121 - 121
  • [3] PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib+antiHER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)
    Metzger, O.
    Mandrekar, S.
    Loibl, S.
    Mundhenke, C.
    Seiler, S.
    Valagussa, P.
    Lim, E.
    Tripathy, D.
    Winer, E. P.
    Huang, C.
    Carey, L.
    Francis, P.
    Miller, K.
    Goetz, M. P.
    Prat, A.
    Loi, S.
    Krop, I.
    Gianni, L.
    Delalogue, S.
    Vaz-Luis, I.
    Dockter, T.
    Lanzillotti, J.
    Ciruelos, E.
    DeMichele, A. M.
    CANCER RESEARCH, 2019, 79 (04)
  • [4] The perspective of anti-HER2 therapy for HER2 positive breast cancer
    Iwata, Hiroji
    ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [5] Sparing chemotherapy with dual HER2 blockade in combination with endocrine therapy for advanced HER2 positive breast cancer
    Werutsky, Gustavo
    Reinert, Tomas
    Fay, Andre Poisl
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S573 - S576
  • [6] Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer
    Matthew Loft
    Sheau Wen Lok
    Richard De Boer
    Laeeq Malik
    Sally Greenberg
    Belinda Yeo
    Angelyn Anton
    Michelle Nottage
    Vanessa Wong
    Louise Nott
    Ian M. Collins
    Javier Torres
    Frances Barnett
    Janine M. Lombard
    Peter Gibbs
    Lucy Gately
    Breast Cancer Research and Treatment, 2023, 198 : 67 - 74
  • [7] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
  • [8] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
  • [9] Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
    Porte, Baptiste
    Carton, Matthieu
    Loirat, Delphine
    Bidard, Francois-Clement
    Haroun, Linda
    Bellesoeur, Audrey
    Kirova, Youlia
    Cottu, Paul
    CANCER RESEARCH, 2021, 81 (04)
  • [10] Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
    Porte, B.
    Carton, M.
    Lerebours, F.
    Brain, E.
    Loirat, D.
    Haroun, L.
    Bellesoeur, A.
    Hamba, S. Bach
    Kirova, Y.
    Cottu, P.
    BREAST, 2020, 54 : 303 - 310
12345